Fausto De Michele
Overview
Explore the profile of Fausto De Michele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaghi A, Antonelli Incalzi R, Barbaglia S, Bilo M, Bini F, Carone M, et al.
Clin Transl Allergy
. 2025 Feb;
15(2):e70037.
PMID: 39924642
Background: Despite the availability of numerous guidelines for asthma management, their recommendations are not consistently implemented in clinical practice. This discrepancy between guidelines and real-world practice among Italian healthcare professionals...
2.
Bilo M, Martini M, Antonicelli L, De Michele F, Vaghi A, Musarra A, et al.
Allergy
. 2024 Dec;
PMID: 39641587
No abstract available.
3.
Antonini D, De Michele F, Micheletto C, Radovanovic D, Basile M, Di Brino E, et al.
Glob Reg Health Technol Assess
. 2024 Nov;
11:223-230.
PMID: 39574805
No abstract available.
4.
Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa M, et al.
J Asthma Allergy
. 2024 Apr;
17:273-290.
PMID: 38562251
Purpose: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching biologic treatment is a strategy adopted to optimize asthma control when...
5.
Vultaggio A, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa M, et al.
Respir Res
. 2023 May;
24(1):135.
PMID: 37210543
Background: The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects. Here we present novel data from the...
6.
Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa M, et al.
J Asthma Allergy
. 2022 Nov;
15:1593-1604.
PMID: 36387835
Purpose: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by...
7.
Caruso C, Cameli P, Altieri E, Aliani M, Bracciale P, Brussino L, et al.
Front Med (Lausanne)
. 2022 Sep;
9:950883.
PMID: 36117962
Background: Severe asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of...
8.
DAmato M, Menzella F, Altieri E, Bargagli E, Bracciale P, Brussino L, et al.
Front Allergy
. 2022 Jun;
3:881218.
PMID: 35769575
Background: Severe eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation. analyses from a pivotal clinical trial...
9.
Menzella F, Bargagli E, Aliani M, Bracciale P, Brussino L, Caiaffa M, et al.
Respir Res
. 2022 Feb;
23(1):36.
PMID: 35183167
Background: Data from phase 3 trials have demonstrated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world study examining the baseline characteristics...
10.
Antonicelli L, Tontini C, Manzotti G, Ronchi L, Vaghi A, Bini F, et al.
Allergy
. 2020 Aug;
76(3):902-905.
PMID: 32794585
No abstract available.